PDCD1 and non-small cell lung carcinoma: Following preliminary efficacy results from the phase I AMBER study (NCT02817633) [149], the combination of cobolimab with the anti-PD-1 inhibitor dostarlimab (TSR-042) showed preliminary anti-tumor activity with acceptable tolerability in a range of advanced solid tumors including NSCLC, melanoma and peritoneal mesothelioma.